Intranasal delivery of KAFAK, a cell-penetrating anti-inflammatory peptide, crossed the blood-brain barrier in TBI mice, reduced proinflammatory cytokines, and restored neurological, memory, and motor function.
Functional restorationIntranasal KAFAK peptide restored neurological, memory, and locomotor performance after moderate TBI — with no surgery or injection needed
What the researchers found
Intranasal KAFAK peptide traversed the BBB in TBI mice, reduced proinflammatory cytokines contributing to secondary injury, and improved or restored neurological, memory, and locomotor function after moderate traumatic brain injury.
Why it matters
TBI affects millions annually and is a leading cause of disability, yet there's no approved treatment for the secondary brain damage caused by chronic inflammation. An intranasal peptide that reduces brain inflammation and restores function could be a game-changer.
The numbers in context
Moderate TBI model with intranasal peptide delivery showing enhanced brain uptake and reduced inflammatory markers.
How the study worked
Murine model of diffuse, moderate TBI. KAFAK administered intranasally (non-invasive). BBB penetration confirmed. Proinflammatory cytokine levels measured. Behavioral tests assessed neurological function, memory, and locomotor performance.
Who was studied
Mice with moderate traumatic brain injury
What this study cannot tell us
Mouse study — TBI models don't fully replicate human brain injury complexity. The exact dose, timing, and duration of KAFAK treatment needed for optimal benefit weren't fully defined. Long-term safety and the sustainability of functional improvements weren't assessed.
How to read the evidence
Preliminary evidence from a single animal study. Results are promising but require replication and dose-optimization before human trials.
When this study was published
Published in 2024; represents cutting-edge intranasal peptide delivery research for neurological conditions.
The bigger picture
Intranasal drug delivery is gaining traction as a way to treat brain conditions without surgery or invasive procedures. Combining this delivery route with anti-inflammatory peptides like KAFAK could open new treatment avenues for TBI, stroke, Alzheimer's, and other neuroinflammatory conditions.
Questions still open
- What is the optimal dosing window after TBI for KAFAK to be maximally effective?
- Could KAFAK intranasal delivery work for chronic TBI inflammation, not just acute injury?
- Would this approach be effective for other neuroinflammatory conditions like stroke or neurodegenerative diseases?
Common questions
How does a nasal spray get drugs into the brain?
Could this be used for concussions or sports-related brain injuries?
Read the original research
Intranasal Delivery of Cell-Penetrating Therapeutic Peptide Enhances Brain Delivery, Reduces Inflammation, and Improves Neurologic Function in Moderate Traumatic Brain Injury.
Pharmaceutics, 16(6)
Citation
Yanamadala, Yaswanthi; Roy, Ritika; Williams, Afrika Alake; Uppu, Navya; Kim, Audrey Yoonsun; DeCoster, Mark A; Kim, Paul; Murray, Teresa Ann. (2024). Intranasal Delivery of Cell-Penetrating Therapeutic Peptide Enhances Brain Delivery, Reduces Inflammation, and Improves Neurologic Function in Moderate Traumatic Brain Injury.. Pharmaceutics, 16(6). https://doi.org/10.3390/pharmaceutics16060774